Limitations and advantages of MS-HRM and bisulfite sequencing for single locus methylation studies

Institute of Human Genetics, University of Aarhus, Wilhelm Meyers Alle 240, Aarhus C, Denmark.
Expert Review of Molecular Diagnostics (Impact Factor: 3.52). 07/2010; 10(5):575-80. DOI: 10.1586/erm.10.46
Source: PubMed


The methylation-sensitive high-resolution melting (MS-HRM) protocol, as described by Wojdacz and Dobrovic, enables detection of a methylated template in an unmethylated background, with sensitivity similar to that of methylation-specific PCR (MSP). Furthermore, MS-HRM-based methylation screening is cost, labor and time efficient in contrast to direct bisulfite sequencing, which, therefore, is unsuitable as a screening method, but is still required to reveal the methylation status of individual CpG sites. In some experiments, detailed information on the methylation status of individual CpGs may be of interest for at least a subset of samples from MS-HRM-based methylation screening. For those samples, sequencing-based methodology has to be coupled with the MS-HRM protocol to investigate the methylation status of single CpG sites within the locus of interest. In this article, we review the limitations and advantages of MS-HRM and bisulfite sequencing protocols for single-locus methylation studies. Furthermore, we provide the insights into interpretation of the results obtained when a combination of the protocols is used for single-locus methylation studies.

Download full-text


Available from: Tine Hørning Morthorst,
  • Source
    • "The sequencing data for samples displaying low-level methylation for the HTR1B MS-HRM assay did not show methylation. However taking into account both superior sensitivity of the MS-HRM over sequencing [9] and the fact that all other low-methylation profiles showed methylation on the sequencing data, we have classified these samples as low-level methylated (Table 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite similar clinical and pathological features, large numbers of breast cancer patients experience different outcomes of the disease. This together with the fact that the incidence of breast cancer is growing worldwide emphasizes an urgent need for identification of new biomarkers for early cancer detection and stratification of patients. We used ultra high-resolution microarrays to compare genome-wide methylation patterns of breast carcinomas (N = 20) and non-malignant breast tissue (N = 5). Biomarker properties of a subset of discovered differentially methylated regions (DMRs) was validated using Methylation Sensitive High Resolution Melting (MS-HRM) in a case control study on a panel of breast carcinomas (N = 275) and non-malignant controls (N = 74). Based on microarray results we selected 19 DMRs for large-scale screening of cases and controls. Analysis of the screening results showed that all DMRs tested displayed significant gains of methylation in the cancer tissue when compared to the levels in control tissue. Interestingly, we have observed two types of locus specific methylation, with loci undergoing either predominantly full or heterogeneous methylation during carcinogenesis. At the same time almost all tested DMRs (17 out of 19) displayed low-level methylation in non-malignant breast tissue independent of locus specific methylation pattern in cases. Specific loci can undergo either heterogeneous or full methylation during carcinogenesis, and loci hypermethylated in cancer frequently show low-level methylation in non-malignant tissue.
    Breast cancer research: BCR 02/2014; 16(1):R17. DOI:10.1186/bcr3612 · 5.49 Impact Factor
  • Source
    • "However, the identification of a single methyl substitution in a gene sequence is challenging, especially since typical amplification processes such as PCR do not preserve the methylation of the original sequence [16]. As such, several methods for identifying methylation in DNA sequences have been developed based on chemical modification [17], biochemical isolation [18] or some combination of these methods [19]. However, if it is "
    [Show abstract] [Hide abstract]
    ABSTRACT: The methylation of cytosine bases in DNA commonly takes place in the human genome and its abnormality can be used as a biomarker in the diagnosis of genetic diseases. In this paper we explore the effects of cytosine methylation on the conductance of DNA. Although the methyl group is a small chemical modification, and has a van der Waals radius of only 2 Å, its presence significantly changes the duplex stability, and as such may also affect the conductance properties of DNA. To determine if charge transport through the DNA stack is sensitive to this important biological modification we perform multiple conductance measurements on a methylated DNA molecule with an alternating G:C sequence and its non-methylated counterpart. From these studies we find a measurable difference in the conductance between the two types of molecules, and demonstrate that this difference is statistically significant. The conductance values of these molecules are also compared with a similar sequence that has been previously studied to help elucidate the charge transport mechanisms involved in direct DNA conductance measurements.
    Journal of Physics Condensed Matter 04/2012; 24(16):164204. DOI:10.1088/0953-8984/24/16/164204 · 2.35 Impact Factor
  • Source
    • "This method however, only confirms the fully methylated status of the CpG sites within primer binding sites. When MIP amplification is used, not only overall methylation status of the amplicon can be qualified by post-PCR technologies like high resolution melting (HRM), but also the methylation pattern within the amplicon can be investigated if MIP amplification is combined with sequencing based technologies (Wojdacz et al., 2010; Candiloro et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The terms methylation quantification and qualification seem self-explanatory however, the results of experiments aiming to quantify or qualify locus specific methylation in clinical material are often difficult to interpret. There are three main reasons for difficulties in understanding methylation status measurement. First, the complexity of locus specific methylation patterns, which oscillate between unmethylated, fully methylated, and heterogeneously methylated. Second the interpretation of methylation-screening results can frequently be problematic due to limitations of the methods used. And finally the specifications of the clinical samples used in laboratory practice frequently hamper the methylation measurement. Thus, the process of quantification and qualification of methylation has to be discussed with consideration of the specific locus analyzed, the methodology used, and the clinical material source used in each specific experiment. The question of the clinical significance of determination of different methylation levels is even more complicated, with substantial evidence for correlation between qualitative methylation changes and clinical features of the disease and at the same time no data showing that different relative levels of methylation alter the disease outcome. The limitations of methylation quantification and qualification are discussed in this mini-review.
    Frontiers in Genetics 02/2012; 3:21. DOI:10.3389/fgene.2012.00021
Show more

Similar Publications